GBS Cases Research Articles

Traumatic Brain Injury and Guillain-Barré Syndrome: Tale of an Illicit Affair—Case Report and Brief Review of Literature

AbstractGuillain-Barré syndrome (GBS) is a common entity in neurology clinics. A variety of etiologies have been implicated in the presentation of GBS. Although rarely reported, traumatic brain injury (TBI) has also been reported to cause GBS. In this article, we report a similar case of GBS that occurred following TBI and the patient presented with acute flaccid paraparesis with intact strength in upper limbs. Paraparesis progressed to quadriparesis simulating a case of spinal injury, without any correlating imaging findings. Nerve conduction study findings, cerebrospinal fluid studies, and clinical examination led to the diagnosis of post-TBI GBS. A review of similar cases reported in literature is also attached. High index of suspicion should be maintained for GBS in all cases of imaging-negative post-TBI limb weakness which may simulate acute spinal injury.

Critical Care in Guillain–Barré Syndrome

AbstractGuillain–Barré syndrome (GBS) is an autoimmune polyneuropathy characterized by hyporeflexic neuromuscular paralysis and albuminocytologic dissociation in the cerebrospinal fluid. It is a postinfectious disorder. The most common antecedent illnesses are respiratory tract infection and Campylobacter jejuni infection. After the antecedent infection, specific antibodies are generated that cross-react with gangliosides in the host culminating in demyelination of the peripheral nerves or nerve roots. Complement activation also contributes to nerve degeneration. Bilateral symmetrical progression of the limb weakness occurs over a period of a few days followed by a plateau phase, after which a recovery phase follows. Generalized hypotonia and hyporeflexia characterize the limb weakness. Cerebrospinal fluid analysis shows albuminocytologic dissociation. About one-third of patients develop respiratory failure. Neuropathic pain is a disturbing symptom in GBS. Dysautonomia is very characteristic of GBS. Erasmus GBS respiratory insufficiency score predicts the need for mechanical ventilation. The weaning process from mechanical ventilation mainly depends on the recovery of vital capacity and inspiratory force. The definitive treatment for GBS consists of plasma exchange or intravenous immunoglobulin therapy both of which are equally efficacious. Seasonal variation has been observed in the occurrence and recovery of GBS. Prognosis of GBS varies widely. Erasmus GBS outcome scale scoring system predicts the ability of the patient to walk independently after 6 months. Several GBS cases have been reported globally during recent pandemic of coronavirus disease 2019. Though GBS is a self-limiting disease, there are quite a few research questions that still remain to be answered.

Guillain-barre syndrome: a paediatric case scenario in a tertiary care hospital at southern India

Background: During hospital ward rounds which was conducted as a part of Doctor of Pharmacy curriculum at Caritas Hospital, Thellakom, the first author got a chance to deal with a case of GBS. Case:12 year old female patient admitted with complaints of weakness on both legs; later diagnosed by the neurologist with demyelinating poly neuropathy and Guillain-Barre Syndrome. Aim: The aim of this particular study was to study more about Guillain-Barre Syndrome which is an auto immune disorder involving peripheral nervous system which usually occurring very rarely, affects 1.55 people per 100,000 in the world’s population, and is characterised by flaccid paralysis of limbs. It typically happens as a result of an earlier illness or other triggering events that excite the immune system of the body and result in the development of various antibodies. Materials and Methods: Analyse various case reports published in various scientific databases like PubMed, Medline, CrossRef etc. Results: This particular case was treated as follows: The treatment involves intravenous infusion of IVIg at a dose which varies according to the weight and severity of condition in each individual. Supplementation with Methyl cobalamin, Alpha lipoic acid, Levo-carnitine, and Vitamin E can improve the neural health and hasten the healing of nerve injuries. Conclusion: Data till now tells us that out of all GBS diagnosed population, 80% have recovered completely, 15% of patients have shown some neurological disabilities, and 5% have succumb to death. Here, the therapy was successful and the patient got discharged from hospital.

Guillain–Barré syndrome after COVID‐19 vaccination with suspected concurrent cytomegalovirus reactivation

AbstractBackgroundGuillain–Barré syndrome (GBS) is an immune‐mediated polyneuropathy most commonly associated with antecedent infections, such as Campylobacter jejuni or viral infections, but vaccination is also known as an antecedent event. In recent years, due to the worldwide pandemic, vaccination against coronavirus disease 2019 (COVID‐19) has widely spread throughout the world. Although surveillance of vaccination‐associated adverse effects is still ongoing, multiple cases of GBS after COVID‐19 vaccination have been reported. However, the exact pathophysiology of COVID‐19 vaccination causing GBS has not been clarified. Not only new‐onset infection, but also reactivation of dormant viral agents, is known to trigger GBS. This reactivation might occur after COVID‐19 vaccination; however, there are no reports of this phenomenon in association with post‐vaccination GBS.Case PresentationA 44‐year‐old immunocompetent woman presented with acute onset weakness in all four limbs 6 days after COVID‐19 vaccination. Neurological examination showed dysphagia, symmetrical weakness, absent tendon reflexes and distal dominant sensory disturbance in all four extremities. Nerve conduction studies were compatible with demyelinating neuropathy, and serum was positive for anti‐GD1a‐IgG antibody. A diagnosis of acute inflammatory demyelinating neuropathy was made. Serological examination on admission suggested concomitant cytomegalovirus reactivation. Plasma exchange rapidly improved her symptoms, including weakness and sensory disturbance, and she was discharged without residual symptoms.ConclusionsThe present case suggests that cytomegalovirus reactivation might play a role in the pathogenesis of GBS associated with COVID‐19 vaccination. Accounting for cytomegalovirus reactivation might reveal unidentified pathophysiology of GBS after COVID‐19 vaccination.

Antecedent Infections and Hospital Outcomes in Demyelinating and Axonal type of Guillain-Barre Syndrome among adult Patients

Background: Many differences are observed with respect to hospital outcome among demyelinating and axonal type of Guillain-Barre Syndrome. Objective: Aims of this study was to compare the hospital outcome at discharge among demyelinating and axonal type of Guillain-Barre syndrome. Methodology: This prospective observational study was conducted from Oct, 2017 to September, 2018 at the National Institute of Neurosciences and Hospital, Dhaka, Bangladesh. All demyelinating and axonal variant of GBS, presented within 2 weeks were included in this study. The clinical parameters were taken for baseline analysis. Outcomes were measured at discharge by MRC score, length of hospital and ICU stay, recovery and death. Results: Out of 108 GBS cases 55 (50.9%) demyelinating & 53 (49.1%) were axonal subtype. Mean age; 40.20 ± 16.26 vs. 32.43 ± 14.93 years in demyelinating vs. axonal cases (p=0.011). Symptom onset and nadir of weakness are quicker in axonal than demyelinating cases (8.47±4.97 vs. 12.36±7.94) (p=0.017) and (6.7 ± 4.5 vs. 8.36 ± 4.59) (p=0.022)] days. Baseline MRC score were (18.04±9.85 vs 12.94±9.91) (p=0.009) demyelinating vs. axonal cases. At discharge, Mean MRC score, length of hospital stay, length of ICU stay were, (22.15±9.38 vs 17.39±9.46; p=0.013); (15.13±17.60 vs 23.58±23.55) days (p=0.038)} and (28.69±23.28 vs 37.0±20.01) days respectively. Conclusion: Hospital outcome of GBS patients is favorable to demyelinating subtype in respect of MRC score, length of hospital stay, length of ICU stay and also death and survivability. Bangladesh Journal of Medical Microbiology, January 2022;16(1):19-24

Cost-effectiveness analysis of maternal vaccination against Group B streptococcus in Japan

BackgroundGroup B Streptococcus (GBS) is a leading pathogen causing life-threatening bacterial infections in neonates (early- or late-onset) and infants, and is associated with preterm and stillbirth. Japan introduced national guidelines to reduce early-onset neonatal GBS disease, with universal prenatal screening and intrapartum antimicrobial prophylaxis (IAP). However, screening/IAP does not prevent GBS associated late-onset disease, preterm or stillbirth. Maternal GBS vaccines in development are targeted at infant GBS disease but may provide benefit across perinatal outcomes. We aimed to assess cost-effectiveness of a future maternal GBS vaccine, for a base case prevention of infant GBS disease in combination with screening/IAP compared to screening/IAP alone. MethodsWe used a decision tree model to estimate cases of infant GBS disease, deaths, and neuro-developmental impairment (NDI), GBS-related stillbirths, and the associated costs and loss in Quality-Adjusted Life Years (QALYs). We calculate the threshold price at which a vaccine would be cost-effective assuming a cost-effectiveness threshold of ¥5 million/QALY. We explored the potential benefit of a maternal GBS vaccine that also prevents preterm birth in a scenario analysis. ResultsMaternal GBS vaccination in Japan could prevent an additional 142 infant GBS cases annually, including 5 deaths and 21 cases of NDI, and 13 stillbirths compared to screening/IAP alone. The incremental cost-effectiveness ratio (ICER) was ¥3.78 million/QALY with a vaccine cost of ¥5,000/dose. If the QALY lost for stillbirth is included, the ICER is reduced to ¥1.78 million/QALY. Median threshold vaccine price was ¥6,900 per dose (95 % uncertainty interval ¥5,100 to ¥9,200 per dose). If maternal GBS vaccination also prevented half of GBS-associated preterm, the ICER would be reduced to ¥1.88 million/QALY. ConclusionsAn effective maternal GBS vaccine is likely to be considered cost-effective in Japan at a price of ¥5,000/dose. Effectiveness against other adverse perinatal outcomes would increase health benefits and cost-effectiveness.

Rare cases of Guillain-Barré syndrome after COVID-19 vaccination, Germany, December 2020 to August 2021.

BackgroundGuillain-Barré syndrome (GBS) has been associated with vaccination against COVID-19.AimWe aimed to compare clinical characteristics and analyse excess GBS cases following administration of different COVID-19 and influenza vaccines in Germany versus the expected numbers estimated from pre-pandemic background incidence rates.MethodsWe analysed safety surveillance data reported to the German national competent authority between 27 December 2020 and 31 August 2021. GBS cases were validated according to Brighton Collaboration (BC) criteria. We conducted observed vs expected (OvE) analyses on cases fulfilling BC criteria levels 1 to 4 for all four European Medicines Agency-approved COVID-19 vaccines and for influenza vaccines.ResultsA total of 214 GBS cases after COVID-19 vaccination had been reported, of whom 156 were eligible for further analysis. Standardised morbidity ratio estimates 3-42 days after vaccination were 0.34 (95% confidence interval (CI): 0.25-0.44) for Comirnaty, 0.38 (95% CI: 0.15-0.79) for Spikevax, 3.10 (95% CI: 2.44-3.88) for Vaxzevria, 4.16 (95% CI: 2.64-6.24) for COVID-19 Vaccine Janssen and 0.60 (95% CI: 0.35-0.94) for influenza vaccines. Bilateral facial paresis was reported in 19.7% and 26.1% of the 156 GBS cases following vaccination with Vaxzevria and COVID-19 Vaccine Janssen, respectively, and only in 6% of cases exposed to Comirnaty.ConclusionThree and four times more GBS cases than expected were reported after vaccination with Vaxzevria and COVID-19 Vaccine Janssen, respectively, therefore GBS might be an adverse event of vector-based vaccines. Bifacial paresis was more common in cases with GBS following vaccination with vector-based than mRNA COVID-19 vaccines.

“PROSPECTIVE OBSERVATIONAL STUDY TO DETERMINE VARIOUS CLINICOBIOCHEMICAL PARAMETERS IN DEVELOPMENT OF LONG COVID”

Long COVID-19 describes illness in people who have recovered from covid-19, still report lasting effects or having unusual symptoms for longer period. It is affected by various comorbid conditions and the biochemical parameters at the time of presentation. This is a Prospective observationsl study conducted at tertiary care hospital in south India. RT PCR conrmed cases were followed on 14, 30, 90 and 180 day's post-discharge telephonically or in person. Results Long-COVID symptoms observed among 55.32% of the study samples. Most symptoms distributed around 30th day of follow-up. Fatigue was the longest symptoms observed (48.9%). Breathlessness (34%), stroke (4.3%), seizure (1.4%), GBS (2.1%) cases respectively. Hypertensive cases account 36.2%, Type 2 DM (29.1%). CAD (10.6%), CCF (7.1%), Asthma/COPD (19.9%/5.7%). Hb, PCV, serum protein, albumin level was lower and increase in TLC, N/L ration, BUN, PT and APTT noted in long covid cases. Prevalence of long COVID was 55.32%. Fatigue was the predominant long covid symp Conclusion tom. Stroke/seizure/GBS/delirium were the least but serious manifestations of long COVID Age morethan 50, males affected more. Patients with HTN, TYPE 2DM, CAD, CCF, asthma/COPD developed more long COVID symptoms. Anaemia, hypalbuminaemia, neutrophilia, increased N/L ratio, elevated SGOT/SGPT on day of admission had higher risk for long COVID.

Guillain-Barré syndrome AMSAN variant in a 90-year-old woman after COVID-19: a case report

BackgroundGuillain-Barré syndrome (GBS) is an inflammatory disease of the peripheral nervous system characterized by rapidly evolving polyneuropathy caused by autoimmune demyelination and/or axonal degeneration. Since SARS-CoV-2 outbreak, several GBS cases following exposure to coronavirus disease-2019 (COVID-19) have been reported in literature, raising the concern of the latter being a potential trigger event for GBS.Case presentationWe report the case of a 90-year-old Caucasian woman who was admitted to our hospital because of fatigue, worsening gait and leg strength, dysphonia, dysarthria and dysphagia, started 3 weeks after being exposed to COVID-19. Based on clinical presentation GBS was suspected, so she performed a lumbar puncture and electromyography, which confirmed the diagnosis of acute motor and sensory axonal neuropathy (AMSAN) variant. We administered high dose of intravenous immunoglobulin with slight neurological improvement. However, after 2 weeks of hospitalization with maximization of care, her physical condition worsen, manifesting severe frailty. The patient was discharged with home support services for managing parenteral nutrition and intense scheduled physiotherapy. A few days later, the patient experienced a further decline in her clinical condition and died at home.ConclusionsTo the best of our knowledge, we report the oldest woman with GBS AMSAN variant after COVID-19 described in the existing literature. Our case supports further research aimed at improving recognition, characterization and prompt management of neurological diseases related to COVID-19 in older patients.

Incidence of Guillain-Barré syndrome in South Korea during the early COVID-19 pandemic.

Guillain-Barré syndrome (GBS) is an immune-mediated polyradiculoneuropathy, often triggered by infection. We aimed to investigate how the incidence of GBS changed in the early stages of the coronavirus 2019 (COVID-19) pandemic when nationwide infections declined due to non-pharmaceutical interventions. We conducted a nationwide population-based retrospective GBS cohort study using data from the Health Insurance Review and Assessment Service of Korea. Patients with new-onset GBS were defined as those who were first hospitalized between 1 January 2016 and 31 December 2020 with an International Classification of Disease, 10th Revision code, for GBS (G61.0) as a primary diagnosis. The incidence of GBS in the pre-pandemic years (2016-2019) was compared with that in the first pandemic year (2020). Nationwide epidemiological data for infections were collected from the national infectious disease surveillance system. A correlation analysis was performed to determine the incidence of GBS and nationwide trends of various infections. Overall, 3,637 new-onset GBS cases were identified. The age-standardized incidence of GBS in the first pandemic year was 1.10 (95% confidence interval, 1.01-1.19) per 100,000 persons. Compared to the first pandemic year, the incidence of GBS during the pre-pandemic years (1.33-1.68/100,000 persons/year) was significantly higher, with incidence rate ratios of 1.21-1.53 (P < 0.001). Nationwide cases of upper respiratory viral infections were significantly reduced in the first pandemic year; however, Campylobacter infections peaked in the summer of the pandemic. The nationwide epidemiology of parainfluenza virus, enterovirus, and Campylobacter infections correlated positively with GBS incidence. The overall GBS incidence decreased in the early stages of the COVID-19 pandemic, which can be attributed to the dramatic reduction in viral illnesses due to public measures.

Fructose promotes ampicillin killing of antibiotic-resistant Streptococcus agalactiae

ABSTRACT Streptococcus agalactiae (GBS) is an important pathogenic bacteria that infected both aquatic animals and human beings, causing huge economic loss. The increasing cases of antibiotic-resistant GBS impose challenges to treat such infection by antibiotics. Thus, it is highly demanded for the approach to tackle antibiotic resistance in GBS. In this study, we adopt a metabolomic approach to identify the metabolic signature of ampicillin-resistant GBS (AR-GBS) that ampicillin is the routine choice to treat infection by GBS. We find glycolysis is significantly repressed in AR-GBS, and fructose is the crucial biomarker. Exogenous fructose not only reverses ampicillin resistance in AR-GBS but also in clinic isolates including methicillin-resistant Staphylococcus aureus (MRSA) and NDM-1 expressing Escherichia coli. The synergistic effect is confirmed in a zebrafish infection model. Furthermore, we demonstrate that the potentiation by fructose is dependent on glycolysis that enhances ampicillin uptake and the expression of penicillin-binding proteins, the ampicillin target. Our study demonstrates a novel approach to combat antibiotic resistance in GBS.

COVID-19-associated Guillain-Barré syndrome in the early pandemic experience in Lombardia (Italy)

ObjectiveTo estimate the incidence and describe clinical characteristics and outcome of GBS in COVID-19 patients (COVID19-GBS) in one of the most hit regions during the first pandemic wave, Lombardia.MethodsAdult patients admitted to 20 Neurological Units between 1/3–30/4/2020 with COVID19-GBS were included as part of a multi-center study organized by the Italian society of Hospital Neuroscience (SNO).ResultsThirty-eight COVID19-GBS patients had a mean age of 60.7 years and male frequency of 86.8%. CSF albuminocytological dissociation was detected in 71.4%, and PCR for SARS-CoV-2 was negative in 19 tested patients. Based on neurophysiology, 81.8% of patients had a diagnosis of AIDP, 12.1% of AMSAN, and 6.1% of AMAN. The course was favorable in 76.3% of patients, stable in 10.5%, while 13.2% worsened, of which 3 died. The estimated occurrence rate in Lombardia ranges from 0.5 to 0.05 GBS cases per 1000 COVID-19 infections depending on whether you consider positive cases or estimated seropositive cases. When we compared GBS cases with the pre-pandemic period, we found a reduction of cases from 165 to 135 cases in the 2-month study period in Lombardia.ConclusionsWe detected an increased incidence of GBS in COVID-19 patients which can reflect a higher risk of GBS in COVID-19 patients and a reduction of GBS events during the pandemic period possibly due to a lower spread of more common respiratory infectious diseases determined by an increased use of preventive measures.

Guillain-Barré Syndrome and Miller Fisher Syndrome in Association With an Arboviral Outbreak: A Brazilian Case Series.

IntroductionGuillain-Barré syndrome (GBS) in association with arboviruses, such as Zika, chikungunya, and dengue, has been previously documented; however, Miller-Fisher Syndrome (MFS) and other GBS subtypes are rarely reported.MethodsWe identified a series of GBS and MFS cases that were followed during the Zika virus outbreak in Salvador, Brazil (2015–2016). Blood and CSF samples were collected for virus diagnosis. In addition, serological studies to verify previous arboviral infection and electromyography (EMG) were performed.ResultsOf the 14 patients enrolled, 10 were diagnosed with GBS, including three GBS subtypes (two cases of bifacial weakness with paresthesia and one case of paraparetic GBS), and four as MFS. IgM antibodies against one or more of three arboviruses were present in 11 (78.6%) patients: anti-zika IgM positivity in eight (57%), anti-Chikungunya IgM in three (21%), and anti-Dengue in one (7%) individual. A single case was positive for both anti-Dengue IgM and anti-Chikungunya IgM, suggesting co-infection. EMG revealed an AIDP pattern in all nine patients analyzed.ConclusionThe current case series contributes to our knowledge on the clinical presentation of arbovirus-associated GBS and its subtypes, including MFS, and serves as an alert to clinicians and other healthcare professionals in regions affected by arbovirus outbreaks. We highlight the importance of recognizing arboviruses in diagnosing GBS and its subtypes.

Guillain-Barre syndrome complicating Neisseria meningitidis infection

Guillain-Barré Syndrome (GBS)-an immune-mediated condition-is the most common cause of acute flaccid paralysis, since the elimination of poliomyelitis. We present a case of GBS as a rare complication of meningococcal meningitis based on clinical features, nerve conduction studies and magnetic resonance imaging (MRI) findings. GBS has rarely been described after meningitis. This case is unique in that our findings show that GBS may be observed after meningococcal meningitis.

Guillain-Barré Syndrome Following Anterior Cervical Spine Surgery and COVID-19 Vaccination: Literature Review with a Case Report

Coronavirus Disease 2019 became a pandemic in March 2020 and vaccines were developed as the most efficient and effective means to control the disease. However, during the early vaccination period, side effects were reported. The following presents a case of GBS with a temporal relationship to COVID-19 vaccination occurring in a patient who recently underwent spinal surgery. In addition, a literature review was performed to draw attention to this neurological complication in association with COVID-19 vaccination and/or spinal surgery.

Guillain-Barre Syndrome Secondary to COVID-19: A case report and short review of other published cases

Background:&#x0D; COVID-19 related Guillain-Barré syndrome has a broad spectrum of presentation. In most reported cases, respiratory symptoms preceded by neurological deficits by one to two weeks, suggesting that the clinical course is mostly post-infectious. In this case report, we present a para-infectious case of GBS with COVID-19.&#x0D; Case presentation:&#x0D; A 37-year-old male patient presented with fever, chills, myalgia, cough, and anosmia. COVID-19 test came positive. He was managed conservatively. On the 7th day of follow-up, he recovered except for a persistent loss of smell and taste. Two weeks after his initial presentation, he reported low back pain and bilateral lower extremity weakness and had a repeat COVID-19 test, which returned positive. His history, physical exam, CSF analysis, nerve conduction, and electromyography test revealed Guillain-Barre Syndrome. We managed GBS with supportive treatment in the hospital, and on follow-up of three months, he recovered fully.&#x0D; Conclusion:&#x0D; In our case, we report a para-infectious case of GBS with C0VID-19, and we managed this case without intravenous immunoglobulin or plasmapheresis. The decision to treat a COVID-19 related GBS case with a traditional GBS treatment option (intravenous immunoglobulin or plasmapheresis) should be taken in conjunction with co-morbidities and a tailored case of case basis.

Characterization of Guillain-Barré Syndrome in the integrated development region of the Federal District and Surrounding Areas (RIDE), Brazil, between 2017 and 2019

IntroductionGuillain-Barré Syndrome (GBS) is an acute immune-mediated polyneuropathy that primarily affects the peripheral nerves. Following the Zika virus outbreak in Latin America, all the Latin American and Brazilian studies conducted reported an increase in the incidence of GBS. The present study aims to characterize the clinical and demographic profile of patients with GBS, according to electrophysiological estudies. MethodsThis is a clinical cohort study based on data from medical charts and interviews conducted at the homes of GBS cases identified by three data sources, admitted to and treated at a tertiary referral hospital between March 2017 and May 2019. ResultsThere was a high level of diagnostic certainty among the 51 GBS cases monitored, with most classified as exhibiting acute inflammatory demyelinating polyneuropathy (AIDP). The majority of the individuals were of working age, with an average schooling level. Diarrhea and upper respiratory tract infection were the previous events most reported. Most cases were admitted to the hospital unable to walk and the main complication identified was aspiration pneumonia. ConclusionThe findings indicate the need to rethink the care of patients with GBS in order to minimize the possibility of future complications during hospitalization that may lead to unfavorable outcomes.

Guillain-Barré syndrome post Covid-19 vaccine: Two case reports

Introduction: Guillain-Barré syndrome is an acute polyradiculoneuropathy which is immune-mediated. It is potentially life-threatening due to respiratory involvement and dysautonomia. It is commonly reported as an adverse event after Campylobacter jejuni infection and following vaccination.&#x0D; Methods: We report two cases of GBS occurring following reception of the first dose of the AstraZeneca COVID-19 vaccine.&#x0D; Cases description: First case of a 70-year-old woman, presenting progressive, symmetric, ascending flaccid tetraparesis with bladder dysfunction which occurred three weeks after the first dose of AstraZeneca Covid-19 vaccine. The cerebrospinal fluid showed an albuminocytologic dissociation; electrophysiological studies showed an acute inflammatory demyelinating polyradiculoneuropathy. The second case was a 68-year-old woman, presenting three weeks after the first dose of the AstraZeneca Covid-19 vaccine, a progressively descending, symmetrical and synchronous tetraplegia, preceded 4 days before by diffuse headaches with involvement of multiple cranial pairs and bladder dysfunction. The cerebrospinal fluid showed an albuminocytologic dissociation, electrophysiological studies showed an acute inflammatory axonal and demyelinating polyradiculoneuropathy.&#x0D; Conclusion: Many cases of GBS after vaccines have been reported including one case following the Pfizer Covid-19 vaccine, yet the pathophysiological mechanisms are not completely elucidated.&#x0D; Keywords: Guillain-Barré syndrome, Adverse event, Covid-19 vaccine.

Guillain-Barré Syndrome After Receiving Sputnik Light COVID-19 Vaccine: A Case Report form Palestine

We present this case of a 50-year-old man with no previous history of COVID-19 infection or recent viral or bacterial infections who presented as a case of Guillain-Barre syndrome 10 days after he received the COVID-19 vaccination. The diagnosis has been made on the basis of physical examination, magnetic resonance imaging (MRI) of the spine, cerebrospinal fluid (CSF) analysis, and electromyography (EMG). The reported cases of GBS following vaccination supported the theory of molecular mimicry as an underlying pathophysiology for this disorder. However, research has not yet identified the exact mechanism at the molecular level. In the best of our knowledge, this is the first case from Palestine to be reported. We hope that our report will encourage further research on this issue and warn medical professionals to consider GBS as a possible diagnosis in patients who present with acute flaccid paralysis (AFP) after vaccination with COVID19.

Guillain-Barré Syndrome After Receiving Sputnik Light COVID-19 Vaccine: A Case Report form Palestine

We present this case of a 50-year-old man with no previous history of COVID-19 infection or recent viral or bacterial infections who presented as a case of Guillain-Barre syndrome 10 days after he received the COVID-19 vaccination. The diagnosis has been made on the basis of physical examination, magnetic resonance imaging (MRI) of the spine, cerebrospinal fluid (CSF) analysis, and electromyography (EMG). The reported cases of GBS following vaccination supported the theory of molecular mimicry as an underlying pathophysiology for this disorder. However, research has not yet identified the exact mechanism at the molecular level. In the best of our knowledge, this is the first case from Palestine to be reported. We hope that our report will encourage further research on this issue and warn medical professionals to consider GBS as a possible diagnosis in patients who present with acute flaccid paralysis (AFP) after vaccination with COVID19.